Home
|
Inbox
|
Search
|
View Abstract
Clinical Outcomes of Alectinib for the Treatment of Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A7350 - Clinical Outcomes of Alectinib for the Treatment of Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
Author Block: P. Luo1, Z. Xia1, J. Fan2, S. Liu1, J. Ye1, X. Xu1, T. Fong1, J. Zhang1; 1Southern Medical University, Guangzhou, China, 2Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China.
Background: Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved by the Food and Drug Administration (FDA) to treat crizotinib-refractory non-small cell lung cancer (NSCLC). We performed this meta-analysis to synthesize the results of different clinical trials to evaluate the efficacy and safety of alectinib. Method: A search of three databases including PubMed, Web of Science and the Cochrane Library was performed from the inception of each database through September 5, 2017. We have pooled the overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and intracranial ORR to evaluate the efficacy of alectinib. Discontinuation rate, rate of dose reduction or interruption due to adverse events as well as the incidence of several adverse events were aggregated to evaluate its safety. Result: A total of 8 studies with 626 patients have been included in our study. The pooled efficacy parameters are as follows: ORR 70% (95%CI 57-82%), DCR 88% (95%CI 82-94%), PFS 9.36 months (95%CI 7.38-11.34), and intracranial ORR 52% (95%CI 45-59%). ALKi-naïve patients tend to have better responses than crizotinib-pretreated patients. The aggregate discontinuation rate is 7% (95%CI 4-10%), and the pooled rate of dose reduction or interruption is 33% (95%CI 24-42%). The incidences of the most adverse events are relatively low, while the incidences of two frequently reported adverse events, myalgia (18%) and anemia (25%), were even higher than with the first-generation ALKi crizotinib. Conclusion: Generally, alectinib is a drug with preferable efficacy and tolerable adverse effects, and it is suitable for the treatment of intracranial metastases.
Author Block: P. Luo1, Z. Xia1, J. Fan2, S. Liu1, J. Ye1, X. Xu1, T. Fong1, J. Zhang1; 1Southern Medical University, Guangzhou, China, 2Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China.
Background: Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved by the Food and Drug Administration (FDA) to treat crizotinib-refractory non-small cell lung cancer (NSCLC). We performed this meta-analysis to synthesize the results of different clinical trials to evaluate the efficacy and safety of alectinib. Method: A search of three databases including PubMed, Web of Science and the Cochrane Library was performed from the inception of each database through September 5, 2017. We have pooled the overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and intracranial ORR to evaluate the efficacy of alectinib. Discontinuation rate, rate of dose reduction or interruption due to adverse events as well as the incidence of several adverse events were aggregated to evaluate its safety. Result: A total of 8 studies with 626 patients have been included in our study. The pooled efficacy parameters are as follows: ORR 70% (95%CI 57-82%), DCR 88% (95%CI 82-94%), PFS 9.36 months (95%CI 7.38-11.34), and intracranial ORR 52% (95%CI 45-59%). ALKi-naïve patients tend to have better responses than crizotinib-pretreated patients. The aggregate discontinuation rate is 7% (95%CI 4-10%), and the pooled rate of dose reduction or interruption is 33% (95%CI 24-42%). The incidences of the most adverse events are relatively low, while the incidences of two frequently reported adverse events, myalgia (18%) and anemia (25%), were even higher than with the first-generation ALKi crizotinib. Conclusion: Generally, alectinib is a drug with preferable efficacy and tolerable adverse effects, and it is suitable for the treatment of intracranial metastases.
|
Home
|
Inbox
|
Search
|